Adc Therapeutics SA

NYSE:ADCT   10:26:52 AM EDT
4.90
-0.07 (-1.41%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)405.78M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$18.14 Million
Adjusted EPS-$0.55
See more estimates
10-Day MA$4.75
50-Day MA$4.64
200-Day MA$2.20
See more pivots

Adc Therapeutics SA Stock, NYSE:ADCT

BiopÃ?Â?le, Route de la Corniche 3B, Epalinges, Vaud 1066
Switzerland
Phone: +41.212.653.02.00
Number of Employees: 162
http://www.adctherapeutics.com

Description

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.